Conclusions

Psychological stress and immune system dysregulation are inextricably intertwined, as has been well described in the psychoneuroimunology literature, and both can exacerbate the signs and conditions we term as aging.  The findings in various disciplines taken as a whole, one is presented with a picture in which stress and immunosenescence do not simply affect the aging process, but quite possibly do substantively create it. 

This unfolding picture, from anecdotal experience to reproducible clinical evidence, is one which presents strategic AIM immunotherapy as a valid, broad-spectrum, anti-aging modality.  In this regard, both as a clinical tool and personal health agent, the long-term efficacy and non-toxic profile of natural rice bran oligo-arabinoxylan AIMs are indeed most promising for adults of any age or state of health. 

Applying AIM in the progressive management of the several major diseases associated with aging thus warrants further study; both in the interests of developing greater clinical acumen, and of expanding our existing database towards a more comprehensive understanding of immunosenescence and its pathophysiologic consequences.  Towards this goal we are highly motivated, and guided by the premise of immunosenescence as aging, we are continually diversifying our AIM research into novel areas, including Alzheimer’s Disease, Inflammatory Bowel Disease (Crohn’s), communicable viral diseases (e.g., HIV and influenza) and vaccine optimization, and impact upon telomere length in vivo.

References

1.          Castle SC.  Clinical relevance of age-related immune dysfunction.  Clinical Infectious Diseases 2000, 31:578-585.

2.          Ramos-Casals M, Garcia-Carrasco M, Brito MP, Lopez-Soto A, Font J.  Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly.  Lupus 2003, 12:341-355.

3.          Denduluri N, Ershler WB.  Aging biology and cancer.  Semin Oncol 2004, 31(2):137-148.

4.          Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA.  Impact of influenza vaccination on seasonal mortality in the US elderly population.  Arch Int Med 2005, 165:265-272.

5.          Blasco MA.  Immunosenescence phenotypes in the telomerase knockout mouse.  Springer Semin Immunopathol 2002, 24:75–85.

6.          Keller SE, Schleifer SJ, Bartlett JA, Shiflett SC, Rameshwar P.  Stress, depression, immunity, and health.  In: Goodkin, K., and Visser, A. P. (Eds.), Psychoneuro-immunology: Stress, mental disorders, and health.  American Psychatric Press, Washington, D.C. 2000.  pp. 1–25.

7.         Heffner KL, Loving TJ, Robles TF, Kiecolt-Glaser JK.  Examining psychosocial factors related to cancer incidence and progression: In search of the silver lining. Brain Behav Immun 2003, 17:S109–S111.

8.          Cooper MA, Fehniger TA, Caligiuri MA.   The biology of human natural killer-cell subsets.  Trends Immunol 2001, 22(11):633-640.

9.          Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA.  Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.  Blood 2001, 97(10):3146-3151.

10.      Solana R, Alonso MC, Pena J.  Natural killer cells in healthy aging.  Exp Gerontol 1999, 34: 435–443.

11.      Delarosa O, Tarazona R, Casado JG, Alonso C, Ostos B, Pena J, Solana R. Vα24+ NKT cells are decreased in elderly humans.  Exp Gerontol 2002, 37:213–217.

12.      Facchini A, Mariani E, Mariani AR, Papa S, Vitale M, Manzoli FA.   Increased number of circulating Leu11+(CD16) large granular lymphocytes and decreased NK activity during human aging.  Clin Exp Immunol 1987, 68(2):340-347.

13.      Remarque E, Pawelec P.  T cell immunosensescence and its clinical relevance in man.  Rev in Clin Gerontol 1998, 8:5-14

14.      Sansoni P, Cossarizza A, Brianti V, Fagoni F, Snelli G, Monti D, Marcarto A, Passeri G, Ortolani C, Forti E.  Lymphocyte Subsets and Natural Killer Cell Activity in Healthy Old People and Centenarians.  Blood 1993, 82:2767-2773.

15.      Hak L, Mysliwska J, Wieckiewicz J, Szyndler K, Trzonkowski P, Siebert J, Mysliwski A.  NK cell compartment in patients with coronary heart disease.  Immunity & Ageing 2007, 4:3.

16.      Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Horsten S.  Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 2003, 134:1-11.

17.      Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al.  Ghrelin inhibits leptin- and activation-induced pro-inflammatory cytokine expression by human monocytes and T cells.  J Clin Invest 2004, 114:57-66.

18.      Fantuzzi G.  Adipose tissue, adipokines, and inflammation.  J Allergy Clin Immunol 2005, 115:911-9.

19.      Tzianabos AO.  Polysaccharide Immunomodulators as Therapeutic Agents: Structural Aspects and Biologic Function.  Clin Microbiol Rev 2000, 13:523-533.

20.      Di Renzo L, Yefendof E, Klein E.  The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).  Eur J Immunol 1991, 21:1755-1758.

21.      Tazawa K, (Ed.),  Biobran/MGN-3 (Rice Bran Arabinoxylan Derivative) Basic and clinical application to integrative medicine.  Iyakushuppan Co., Japan 2006. ISBN-10: 4990094042.

22.      Ghoneum M, Gollapudi S.  Modified arabinoxylan rice bran (RBAC/Biobran) sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis.  Cancer Lett 2003, 201(1):41-9.

23.      Tazawa K, Namikawa H, Oida N, Masada M, Maeda H.  Scavenging activity of modified arabinoxylane from rice bran (Biobran/MGN-3) with natural killer cell activity on free radicals.  Biotherapy 2000, 14:493-495.

24.     Ghoneum M, Jewett A.  Production of Tumor Necrosis Factor-α and Interferon-γ from Human Peripheral Blood Lymphocytes by MGN-3, a Modified Arabinoxylan from Rice Bran, and Its Synergy with Interleukin-2 In Vitro.  Cancer Det Prev 2000, 24(4):314-324.

25.      Ghoneum M, Matsuura M. Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). Int J Immunopathol Pharmacol 2004, 17(3):283-292.

26.      Ichihashi K.  Experience with administration of modified arabinoxylan from rice bran in patients with Rheumatoid Arthritis.  Clin Pharmacol and Therapy 2004, 14(4):459-463.

27.      Ghoneum M , Matsuura M, Gollapudi S.  Modified Arabinoxylan Rice Bran (MGN-3/Biobran) Enhances Intracellular Killing of Microbes by Human Phagocytic Cells In Vitro.  Int J Immunopathol Pharmacol 2008, 21(1):[page assignment pending].

28.      Gollapudi S, Ghoneum M.  MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin.  Cancer Det Prev 2008, 32:1-6.

29.      Badr El-Din N, Noaman E, Ghoneum M.  In Vivo Tumor Inhibitory Effects of Nutritional Rice Bran Supplement MGN-3/Biobran on Ehrlich Carcinoma-Bearing Mice.  Nutrition and Cancer 2008, 60(2), 1–10.

30.      Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system.  Curr Opin Immunol 2005, 17:457–62.

31.      Burns EA, Goodwin JS. Immunodeficiency of aging.  Drugs Aging 1997, 11: 374–397.

32.      Ghoneum M.  Anti-HIV activity in vitro of MGN-3, an activated arabinoxylane from rice bran.  Biochem Biophys Res Commun 1998, 243(1):25-9.

Acknowledgements

*- RBAC (also referred to in the literature under the proprietary names, “MGN-3” and “Biobran”) was provided by Daiwa Pharmaceuticals Co., Ltd., Tokyo, Japan.